Sep 17, 2020

Heart Valve Disease

Information about heart valve disease and heart valve replacement.

The following media kits are made available to provide reporters with background information on the range of Medtronic therapies and the conditions they treat.

	Sep 23, 2019 Medtronic Announces FDA Approval and U.S. Launch of Next-Generation Evolut™ PRO+ TAVR System for Treatment of Symptomatic Severe Aortic Stenosis Patients Improved Functionality Across Four Valve Sizes and Lowest Delivery Profile on the Market, the Evolut PRO+ TAVR System Launches in U.S. as TAVR Patient Population Grows DUBLIN, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of...
	Aug 16, 2019 Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality Expanded TAVR Indication to Younger, More Active Patients Signals Groundbreaking Shift in the Future Treatment of Heart Valve Disease DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR)...
	Mar 21, 2017 Medtronic Receives FDA Approval for CoreValve(TM) Evolut(TM) Pro Transcatheter Valve with Advanced Sealing First-Ever Data at ACC.17 Confirms Safety and Efficacy of New Self-Expanding, Recapturable Heart Valve at 30-Days with High Survival, Low Stroke and Minimal Paravalvular Leak DUBLIN - March 22, 2017 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM) Evolut(TM) PRO valve for the treatment of...
	Jul 10, 2017 Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval Self-Expanding CoreValve(TM) Evolut(TM)TAVR Platform with Excellent Procedural Safety and Proven Valve Performance Helps Address Needs of Intermediate-Risk Patients DUBLIN - July 10, 2017 - Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic...
	Oct 26, 2016 Medtronic Announces FDA Approval of New Recaptureable TAVR System Available for Severe Aortic Stenosis Patients with Large Anatomies Launch of 34 mm Self-Expanding Evolut R Device Expands TAVR Treatment to Patients Who Could Not be Treated Previously DUBLIN - Oct. 26, 2016 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM) Evolut(TM) R 34 mm valve-the largest...
	Aug 2, 2017 Medtronic Expands Heart Valve Portfolio with FDA Approval and CE Mark of the Avalus(TM) Surgical Aortic Valve Introduction of New Pericardial Aortic Heart Valve in the U.S. and Europe Reinforces Company's Commitment to Comprehensive Solutions to Heart Valve Disease DUBLIN - August 2, 2017 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus(TM) pericardial aortic...